Barclays analyst Andrew Mok raised the firm’s price target on Encompass Health (EHC) to $150 from $141 and keeps an Overweight rating on the shares. The company reported a modest Q4 beat, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC: